Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12-11

AUTHORS

Sarah J. Pugh, Mark A. Fletcher, Apostolos Charos, Lynda Imekraz, Matt Wasserman, Raymond Farkouh

ABSTRACT

INTRODUCTION: To evaluate the expected impact of the Algeria national immunization program (NIP) and potential impact for a Tunisia NIP, this study assessed the public health and economic value of vaccination, through a cost-effectiveness analysis, for a PCV13 or PCV10 NIP, compared with no vaccination. METHODS: A decision-analytic model was programmed in Microsoft Excel™ and adapted to evaluate the clinical and economic outcomes of PCV vaccination. Assuming a steady state, the model estimated invasive pneumococcal disease (IPD; bacteremia and meningitis), all-cause pneumonia (inpatient and outpatient), and all-cause otitis media cases as well as the associated costs from a payer perspective. The base case scenario assumed direct effects for both PCVs and indirect effects (against IPD) for PCV13 only. RESULTS: In Algeria, compared with no vaccination program, PCV13 would save 2177 lives and avoid nearly 349,000 cases of IPD, pneumonia, and AOM at a highly cost-effective value of $308 per QALY. In Tunisia, PCV13 would save 308 lives and avoid 1305 cases of IPD, 4833 cases of pneumonia, and 54,957 cases of AOM at a highly cost-effective value of $848 per QALY. PCV10 prevented 1224 deaths and 270,483 cases of disease in Algeria and prevented 172 deaths and 56,610 cases in Tunisia. PCV10 was cost-effective in both Algeria at $731/QALY and in Tunisia at $1366/QALY. CONCLUSION: The ongoing NIP in Algeria is projected to reduce the impact and economic toll of pneumococcal disease in Algeria. If an NIP were also introduced in Tunisia, a commensurate impact would be expected. PCV NIPs are highly cost-effective, highly impactful public health interventions. FUNDING: Pfizer. More... »

PAGES

63-74

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40121-018-0226-x

DOI

http://dx.doi.org/10.1007/s40121-018-0226-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110536188

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30539417


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pfizer, Collegeville, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, Collegeville, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pugh", 
        "givenName": "Sarah J.", 
        "id": "sg:person.07677333573.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07677333573.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.476471.7", 
          "name": [
            "Pfizer, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fletcher", 
        "givenName": "Mark A.", 
        "id": "sg:person.01003157107.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003157107.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Walton Oaks, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer, Walton Oaks, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charos", 
        "givenName": "Apostolos", 
        "id": "sg:person.0654117003.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654117003.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.476471.7", 
          "name": [
            "Pfizer, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imekraz", 
        "givenName": "Lynda", 
        "id": "sg:person.0700562437.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700562437.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wasserman", 
        "givenName": "Matt", 
        "id": "sg:person.011160316561.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011160316561.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Collegeville, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, Collegeville, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Farkouh", 
        "givenName": "Raymond", 
        "id": "sg:person.0762674162.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762674162.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12962-015-0032-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035161469", 
          "https://doi.org/10.1186/s12962-015-0032-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2334-11-323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019548542", 
          "https://doi.org/10.1186/1471-2334-11-323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0602-551b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009367418", 
          "https://doi.org/10.1038/nm0602-551b"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2334-12-101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024603263", 
          "https://doi.org/10.1186/1471-2334-12-101"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12-11", 
    "datePublishedReg": "2018-12-11", 
    "description": "INTRODUCTION: To evaluate the expected impact of the Algeria national immunization program (NIP) and potential impact for a Tunisia NIP, this study assessed the public health and economic value of vaccination, through a cost-effectiveness analysis, for a PCV13 or PCV10 NIP, compared with no vaccination.\nMETHODS: A decision-analytic model was programmed in Microsoft Excel\u2122 and adapted to evaluate the clinical and economic outcomes of PCV vaccination. Assuming a steady state, the model estimated invasive pneumococcal disease (IPD; bacteremia and meningitis), all-cause pneumonia (inpatient and outpatient), and all-cause otitis media cases as well as the associated costs from a payer perspective. The base case scenario assumed direct effects for both PCVs and indirect effects (against IPD) for PCV13 only.\nRESULTS: In Algeria, compared with no vaccination program, PCV13 would save 2177 lives and avoid nearly 349,000 cases of IPD, pneumonia, and AOM at a highly cost-effective value of $308 per QALY. In Tunisia, PCV13 would save 308 lives and avoid 1305 cases of IPD, 4833 cases of pneumonia, and 54,957 cases of AOM at a highly cost-effective value of $848 per QALY. PCV10 prevented 1224 deaths and 270,483 cases of disease in Algeria and prevented 172 deaths and 56,610 cases in Tunisia. PCV10 was cost-effective in both Algeria at $731/QALY and in Tunisia at $1366/QALY.\nCONCLUSION: The ongoing NIP in Algeria is projected to reduce the impact and economic toll of pneumococcal disease in Algeria. If an NIP were also introduced in Tunisia, a commensurate impact would be expected. PCV NIPs are highly cost-effective, highly impactful public health interventions.\nFUNDING: Pfizer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40121-018-0226-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050275", 
        "issn": [
          "2193-8229", 
          "2193-6382"
        ], 
        "name": "Infectious Diseases and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "national immunization program", 
      "pneumococcal disease", 
      "immunization programs", 
      "invasive pneumococcal disease", 
      "pneumococcal conjugate vaccine", 
      "cases of pneumonia", 
      "otitis media cases", 
      "cases of IPD", 
      "public health interventions", 
      "cases of AOM", 
      "decision analytic model", 
      "cost-effectiveness analysis", 
      "cases of disease", 
      "cause pneumonia", 
      "PCV vaccination", 
      "conjugate vaccine", 
      "vaccination program", 
      "payer perspective", 
      "PCV13", 
      "vaccination", 
      "health interventions", 
      "pneumonia", 
      "QALY", 
      "disease", 
      "economic toll", 
      "PCV10", 
      "cost-effective value", 
      "public health", 
      "death", 
      "base case scenario", 
      "direct effect", 
      "economic outcomes", 
      "cases", 
      "AOM", 
      "vaccine", 
      "commensurate impact", 
      "economic value", 
      "Microsoft Excel", 
      "outcomes", 
      "intervention", 
      "PCV", 
      "Pfizer", 
      "life", 
      "health", 
      "indirect effects", 
      "effect", 
      "program", 
      "IPD", 
      "potential impact", 
      "media cases", 
      "case scenario", 
      "impact", 
      "toll", 
      "study", 
      "Tunisia", 
      "values", 
      "cost", 
      "Excel", 
      "Algeria", 
      "steady state", 
      "analysis", 
      "model", 
      "perspective", 
      "scenarios", 
      "state", 
      "Algeria national immunization program", 
      "Tunisia NIP", 
      "PCV10 NIP", 
      "ongoing NIP", 
      "PCV NIPs", 
      "impactful public health interventions"
    ], 
    "name": "Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria", 
    "pagination": "63-74", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110536188"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40121-018-0226-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30539417"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40121-018-0226-x", 
      "https://app.dimensions.ai/details/publication/pub.1110536188"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_771.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40121-018-0226-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40121-018-0226-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40121-018-0226-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40121-018-0226-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40121-018-0226-x'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      22 PREDICATES      101 URIs      89 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40121-018-0226-x schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N3c7e54bf9c0e469eb9dc385b65e431d1
4 schema:citation sg:pub.10.1038/nm0602-551b
5 sg:pub.10.1186/1471-2334-11-323
6 sg:pub.10.1186/1471-2334-12-101
7 sg:pub.10.1186/s12962-015-0032-1
8 schema:datePublished 2018-12-11
9 schema:datePublishedReg 2018-12-11
10 schema:description INTRODUCTION: To evaluate the expected impact of the Algeria national immunization program (NIP) and potential impact for a Tunisia NIP, this study assessed the public health and economic value of vaccination, through a cost-effectiveness analysis, for a PCV13 or PCV10 NIP, compared with no vaccination. METHODS: A decision-analytic model was programmed in Microsoft Excel™ and adapted to evaluate the clinical and economic outcomes of PCV vaccination. Assuming a steady state, the model estimated invasive pneumococcal disease (IPD; bacteremia and meningitis), all-cause pneumonia (inpatient and outpatient), and all-cause otitis media cases as well as the associated costs from a payer perspective. The base case scenario assumed direct effects for both PCVs and indirect effects (against IPD) for PCV13 only. RESULTS: In Algeria, compared with no vaccination program, PCV13 would save 2177 lives and avoid nearly 349,000 cases of IPD, pneumonia, and AOM at a highly cost-effective value of $308 per QALY. In Tunisia, PCV13 would save 308 lives and avoid 1305 cases of IPD, 4833 cases of pneumonia, and 54,957 cases of AOM at a highly cost-effective value of $848 per QALY. PCV10 prevented 1224 deaths and 270,483 cases of disease in Algeria and prevented 172 deaths and 56,610 cases in Tunisia. PCV10 was cost-effective in both Algeria at $731/QALY and in Tunisia at $1366/QALY. CONCLUSION: The ongoing NIP in Algeria is projected to reduce the impact and economic toll of pneumococcal disease in Algeria. If an NIP were also introduced in Tunisia, a commensurate impact would be expected. PCV NIPs are highly cost-effective, highly impactful public health interventions. FUNDING: Pfizer.
11 schema:genre article
12 schema:inLanguage en
13 schema:isAccessibleForFree true
14 schema:isPartOf N8e3e9f0392ac42578099197abc6bfa74
15 Ne5833cc606654f80a1da8c7e8aa771be
16 sg:journal.1050275
17 schema:keywords AOM
18 Algeria
19 Algeria national immunization program
20 Excel
21 IPD
22 Microsoft Excel
23 PCV
24 PCV NIPs
25 PCV vaccination
26 PCV10
27 PCV10 NIP
28 PCV13
29 Pfizer
30 QALY
31 Tunisia
32 Tunisia NIP
33 analysis
34 base case scenario
35 case scenario
36 cases
37 cases of AOM
38 cases of IPD
39 cases of disease
40 cases of pneumonia
41 cause pneumonia
42 commensurate impact
43 conjugate vaccine
44 cost
45 cost-effective value
46 cost-effectiveness analysis
47 death
48 decision analytic model
49 direct effect
50 disease
51 economic outcomes
52 economic toll
53 economic value
54 effect
55 health
56 health interventions
57 immunization programs
58 impact
59 impactful public health interventions
60 indirect effects
61 intervention
62 invasive pneumococcal disease
63 life
64 media cases
65 model
66 national immunization program
67 ongoing NIP
68 otitis media cases
69 outcomes
70 payer perspective
71 perspective
72 pneumococcal conjugate vaccine
73 pneumococcal disease
74 pneumonia
75 potential impact
76 program
77 public health
78 public health interventions
79 scenarios
80 state
81 steady state
82 study
83 toll
84 vaccination
85 vaccination program
86 vaccine
87 values
88 schema:name Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
89 schema:pagination 63-74
90 schema:productId N5efaad4ea5f84acd9a129c11a0a4a087
91 Nc09ab233634a4479aa637df673b45c21
92 Nc4c5829d7e1543f58470aafb57da1ba1
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110536188
94 https://doi.org/10.1007/s40121-018-0226-x
95 schema:sdDatePublished 2021-12-01T19:40
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Nea69eeb4418f4a7b9fb6b3500f1a9131
98 schema:url https://doi.org/10.1007/s40121-018-0226-x
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N0c261eacac884ba69a3612ea3070f2e3 rdf:first sg:person.01003157107.33
103 rdf:rest Nf3a777e305084dbbb86fa4b55296dd7c
104 N1cb635949e8c4e3fb1bcb9afe3111836 rdf:first sg:person.0700562437.21
105 rdf:rest N4ebfddbefb8141fb975d3903c4ef427d
106 N3c7e54bf9c0e469eb9dc385b65e431d1 rdf:first sg:person.07677333573.23
107 rdf:rest N0c261eacac884ba69a3612ea3070f2e3
108 N489fd4ab3ae94ca48b61d3fad907efa0 rdf:first sg:person.0762674162.64
109 rdf:rest rdf:nil
110 N4ebfddbefb8141fb975d3903c4ef427d rdf:first sg:person.011160316561.65
111 rdf:rest N489fd4ab3ae94ca48b61d3fad907efa0
112 N5efaad4ea5f84acd9a129c11a0a4a087 schema:name doi
113 schema:value 10.1007/s40121-018-0226-x
114 rdf:type schema:PropertyValue
115 N8e3e9f0392ac42578099197abc6bfa74 schema:issueNumber 1
116 rdf:type schema:PublicationIssue
117 Nc09ab233634a4479aa637df673b45c21 schema:name pubmed_id
118 schema:value 30539417
119 rdf:type schema:PropertyValue
120 Nc4c5829d7e1543f58470aafb57da1ba1 schema:name dimensions_id
121 schema:value pub.1110536188
122 rdf:type schema:PropertyValue
123 Ne5833cc606654f80a1da8c7e8aa771be schema:volumeNumber 8
124 rdf:type schema:PublicationVolume
125 Nea69eeb4418f4a7b9fb6b3500f1a9131 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 Nf3a777e305084dbbb86fa4b55296dd7c rdf:first sg:person.0654117003.93
128 rdf:rest N1cb635949e8c4e3fb1bcb9afe3111836
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
133 schema:name Public Health and Health Services
134 rdf:type schema:DefinedTerm
135 sg:journal.1050275 schema:issn 2193-6382
136 2193-8229
137 schema:name Infectious Diseases and Therapy
138 schema:publisher Springer Nature
139 rdf:type schema:Periodical
140 sg:person.01003157107.33 schema:affiliation grid-institutes:grid.476471.7
141 schema:familyName Fletcher
142 schema:givenName Mark A.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003157107.33
144 rdf:type schema:Person
145 sg:person.011160316561.65 schema:affiliation grid-institutes:grid.410513.2
146 schema:familyName Wasserman
147 schema:givenName Matt
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011160316561.65
149 rdf:type schema:Person
150 sg:person.0654117003.93 schema:affiliation grid-institutes:grid.418566.8
151 schema:familyName Charos
152 schema:givenName Apostolos
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654117003.93
154 rdf:type schema:Person
155 sg:person.0700562437.21 schema:affiliation grid-institutes:grid.476471.7
156 schema:familyName Imekraz
157 schema:givenName Lynda
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700562437.21
159 rdf:type schema:Person
160 sg:person.0762674162.64 schema:affiliation grid-institutes:grid.410513.2
161 schema:familyName Farkouh
162 schema:givenName Raymond
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762674162.64
164 rdf:type schema:Person
165 sg:person.07677333573.23 schema:affiliation grid-institutes:grid.410513.2
166 schema:familyName Pugh
167 schema:givenName Sarah J.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07677333573.23
169 rdf:type schema:Person
170 sg:pub.10.1038/nm0602-551b schema:sameAs https://app.dimensions.ai/details/publication/pub.1009367418
171 https://doi.org/10.1038/nm0602-551b
172 rdf:type schema:CreativeWork
173 sg:pub.10.1186/1471-2334-11-323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019548542
174 https://doi.org/10.1186/1471-2334-11-323
175 rdf:type schema:CreativeWork
176 sg:pub.10.1186/1471-2334-12-101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024603263
177 https://doi.org/10.1186/1471-2334-12-101
178 rdf:type schema:CreativeWork
179 sg:pub.10.1186/s12962-015-0032-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035161469
180 https://doi.org/10.1186/s12962-015-0032-1
181 rdf:type schema:CreativeWork
182 grid-institutes:grid.410513.2 schema:alternateName Pfizer, Collegeville, PA USA
183 Pfizer, New York, NY USA
184 schema:name Pfizer, Collegeville, PA USA
185 Pfizer, New York, NY USA
186 rdf:type schema:Organization
187 grid-institutes:grid.418566.8 schema:alternateName Pfizer, Walton Oaks, UK
188 schema:name Pfizer, Walton Oaks, UK
189 rdf:type schema:Organization
190 grid-institutes:grid.476471.7 schema:alternateName Pfizer, Paris, France
191 schema:name Pfizer, Paris, France
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...